Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

7.690 -0.030 (-0.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Beyond The Numbers: 7 Analysts Discuss Prothena Corp Stock
 
Via Benzinga
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
 
Via Benzinga
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Earnings Scheduled For May 8, 2025
 
Via Benzinga
A Look Ahead: Prothena Corp's Earnings Forecast
 
Via Benzinga
Prothena to Report First Quarter 2025 Financial Results on May 8
From Prothena Corporation plc
Via Business Wire
Prothena Corp Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Prothena Corporation plc
Via Business Wire
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (5 Ratings)
 
Via Benzinga
Demystifying Prothena Corp: Insights From 6 Analyst Reviews
 
Via Benzinga
Expert Ratings For Prothena Corp
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Earnings Preview For Prothena Corp
 
Via Benzinga
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Prothena Announces Board of Directors Update
From Prothena Corporation plc
Via Business Wire
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Topics Stocks
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
The drug technically missed the study's primary goal. But there's still promise it could work in specific patients. 
Via Investor's Business Daily
Breaking Down Prothena Corp: 4 Analysts Share Their Views
 
Via Benzinga
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses. 
Via Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
From Prothena Corporation plc
Via Business Wire
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Third Quarter 2024 Financial Results on November 12
From Prothena Corporation plc
Via Business Wire
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Dow Dips 300 Points; Emcore Shares Spike Higher
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.